At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓Histologically confirmed indolent B-cell lymphoma including follicular (grade 1-3A), marginal zone, or follicle center lymphoma
- ✓Any stage disease
- ✓Initial, refractory, or relapsed disease with evidence of progression if relapse at treatment site
- ✕T-cell lymphoma
- ✕Currently receiving treatment for small cell or chronic lymphocytic lymphoma
- ✕Grade 3B follicular lymphoma
- ✕Pregnant women
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MC230808 Reduced Dose Hypofractionated Radiotherapy (3Gy x 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial
In Brief
A Phase 2 clinical trial evaluating Computed Tomography, Endoscopic Procedure, and 4 other interventions for Indolent B-Cell Non-Hodgkin Lymphoma and 4 related conditions. Currently recruiting, targeting 112 participants across 7 sites.
Signals
Detailed Summary
This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.
Study Details
Timeline
Interventions
Undergo CT or PET/CT
Undergo endoscopy
Undergo ISRT in 3 fractions
Undergo ISRT in 12 fractions
Undergo PET/CT
Ancillary studies